An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized

J Allergy Clin Immunol. 2014 Mar;133(3):914-5.e2. doi: 10.1016/j.jaci.2013.10.015. Epub 2013 Dec 18.

Authors

Pınar Uysal¹, Esben Eller¹, Charlotte G Mortz¹, Carsten Bindslev-Jensen²

Affiliations

¹ Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, DK-5000 Odense C, Denmark.
² Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis, Odense University Hospital, University of Southern Denmark, DK-5000 Odense C, Denmark. Electronic address: carsten.bindslev-Jensen@rsyd.dk.

PMID: 24360324
DOI: 10.1016/j.jaci.2013.10.015

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Algorithms*
Anti-Allergic Agents / administration & dosage*
Antibodies, Anti-Idiotypic / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Child
Chronic Disease
Female
Humans
Male
Middle Aged
Omalizumab
Time Factors
Urticaria / drug therapy*

Substances

Anti-Allergic Agents
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal, Humanized
Omalizumab